# iGrow Venture Partners

> iGrow Venture Partners is a VC fund backing FinTech, Finance and Manufacturing. See 4 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Total investments: 4
- Last investment: Jun 2026
- Lead investor: 75%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/igrow-ventures-partners
- Website: https://www.igrow.vc

iGrow Venture Partners is an investment firm.

## Round sizes

| Stage | Round size |
| --- | --- |
| Series B | $14M–$46M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| FinTech | 1 | 25% |
| Finance | 1 | 25% |
| Manufacturing | 1 | 25% |
| Pharmaceutical | 1 | 25% |
| Financial Services | 1 | 25% |

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 1 | 25% |
| Series B | 1 | 25% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Greece | 1 | 25% |
| United Kingdom | 1 | 25% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| xCures | The convergence of genomics, precision medicine, and AI have created an unprecedented moment in the world of oncology. But the drug-centric way in which treatments are developed and the haphazard way in which knowledge about those treatments is captured and delivered to the point of care does not serve patients well. xCures is changing that, withan AI-based precision oncology platform that tightly integrates cancer research and care.The xCures platform runs a perpetual trial that captures Real World Evidence (RWE) to continuously learn from all patients, on all treatments, all the time. It coordinates treatment recommendations across all patients and institutions to match patients with the treatments that work. And it packages RWE for use by stakeholders across oncology, slashing the time and cost of drug development and saving lives. | $46M | Series B | Jun 24, 2026 |  |
| Antogen | Antogen is a specialized Contract Research Organization (CRO) that provides immunopeptidomics services to identify and quantify peptide–HLA ligands directly from biological samples, platform accelerates discovery and translational pipelines across oncology, immunotherapy development, and autoimmune disease research. |  | Seed | Jun 09, 2026 |  |
| Alvion Pharmaceuticals SMSA | Alvion Pharmaceuticals is a science-driven and intellectual property powerhouse, propelling rapid growth in the pharmaceutical industry by developing and manufacturing an extensive portfolio of proprietary products.Partnering with cutting-edge R&D centers, Alvion operates as a private and independent company, focusing on the research anddevelopment of non-infringing, high-value medicines. With a diversified business model, Alvion is filling and supplying generic and added value products to its pharmaceutical partners worldwide.Our commitment to excellence has enabled us to license our products and services across all Europe, MENA, Canada, Australia, South Africa, APAC, and LATAM, supporting a robust business model.With headquarters in Athens, Greece, and Galway, Ireland, Alvion stands as a preferred B2B partner for multinational and major pharmaceutical companies globally. We pride ourselves on being one of Southern Europe's most passionate and customer driven pharmaceutical companies, aiming to be vertically integrated by 2029. |  | Seed | Apr 04, 2026 |  |
| Plum Fintech | Plum Fintech is the developer of Plum, a smart money app. Founded by Victor Trokoudes and Alex Michael in 2016, Plum automates the parts of personal finance that people find difficult or don’t have time for, with effortless saving, empowered spending and accessible investing. It offers the best financial products to help customers grow their moneyfor life, from pensions to tax-wrappers. Today, Plum has helped 2m people across Europe and has expanded to 10 countries. The team of 200+ are based in the company's London HQ as well as offices in Athens, Greece and Nicosia, Cyprus. | $13.7M | Series B | Jul 23, 2024 |  |

4 of 4 investments shown.

## Co-investors
- [Eurobank](https://shizune.co/investors/profile/eurobank) — VC Fund, 1 deal together
- [Finberg](https://shizune.co/investors/profile/finberg) — VC Fund, 1 deal together
- [GKCC](https://shizune.co/investors/profile/gkcc) — VC Fund, 1 deal together
- [Innovius Capital](https://shizune.co/investors/profile/innovius-capital) — VC Fund, 1 deal together
- [Spring Mountain Capital](https://shizune.co/investors/profile/spring-mountain-capital) — VC Fund, 1 deal together
- [Ventura Capital](https://shizune.co/investors/profile/ventura-capital) — VC Fund, 1 deal together

## Similar investors

### Similar industry
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

### Similar country
- [VentureFriends](https://shizune.co/investors/profile/venturefriends) — VC Fund
- [Genesis Ventures](https://shizune.co/investors/profile/genesis-ventures-e8a8) — VC Fund
- [Openfund](https://shizune.co/investors/profile/openfund) — VC Fund

## Featured in investor lists
- [Manufacturing Investors in Greece](https://shizune.co/investors/manufacturing-investors-greece)
- [Manufacturing VC Funds in Greece](https://shizune.co/investors/manufacturing-vc-funds-greece)
- [Health Care Investors in Greece](https://shizune.co/investors/health-care-investors-greece)
- [Health Care VC Funds in Greece](https://shizune.co/investors/health-care-vc-funds-greece)
- [Climate Investors in Greece](https://shizune.co/investors/climate-investors-greece)

## FAQ

### What does iGrow Venture Partners invest in?

iGrow Venture Partners invests primarily in FinTech, Finance and Manufacturing startups, most often at Seed and Series B stage. Most of the 4 investments tracked by Shizune back companies in Greece. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is iGrow Venture Partners's check size?

iGrow Venture Partners typically joins rounds of $14M–$46M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds iGrow Venture Partners participates in.

### When did iGrow Venture Partners last invest?

The most recent investment recorded for iGrow Venture Partners closed in Jun 2026. Shizune tracks 4 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co